Jasplakinolide (Synonyms: NSC 613009) |
| Catalog No.GC17312 |
stabilizes pre-formed actin filaments and inhibits their disassembly
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 102396-24-7
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Jasplakinolide is a natural macrocyclic peptide first isolated from a marine sponge. It potently inhibits the proliferation of PC3 prostate carcinoma cells (IC50 = 35 nM) by binding F-actin (KD = 15 nM).[1] This binding of jasplakinolide to actin, which is competitive with phalloidin, stabilizes actin filaments in vitro but disrupts actin filaments and induces irregular polymerization of monomeric actin in vivo.[1],[2] This compound is used to investigate the role of actin in diverse cellular roles, such as motility, transport, and development.[3],[4]
Reference:
[1]. Bubb, M.R., Senderowicz, A.M.J., Sausville, E.A., et al. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. The Journal of Biological Chemisty 269(21), 14869-14871 (1994).
[2]. Bubb, M.R., Spector, I., Beyer, B.B., et al. Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations. The Journal of Biological Chemisty 275(7), 5163-5170 (2000).
[3]. Van Goor, D., Hyland, C., Schaefer, A.W., et al. The role of actin turnover in retrograde actin network flow in neuronal growth cones. PLoS One 7(2), (2012).
[4]. Zhang, X., Cui, X., Cheng, L., et al. Actin stabilization by jasplakinolide affects the function of bone marrow-derived late endothelial progenitor cells. PLoS One 7(11), (2012).
| Cas No. | 102396-24-7 | SDF | |
| Synonyms | NSC 613009 | ||
| Chemical Name | (4R,7R,10S,13R,17R,19S,E)-7-((2-bromo-1H-indol-3-yl)methyl)-4-(4-hydroxyphenyl)-8,10,13,15,17,19-hexamethyl-1-oxa-5,8,11-triazacyclononadec-15-ene-2,6,9,12-tetraone | ||
| Canonical SMILES | BrC(NC1=CC=CC=C21)=C2C[C@H](C(N[C@@H](C(C=C3)=CC=C3O)CC(O[C@@H](C)C[C@@H](C)C=C(C)C[C@@H](C)C(N[C@H]4C)=O)=O)=O)N(C)C4=O | ||
| Formula | C36H45BrN4O6 | M.Wt | 709.67 |
| Solubility | DMSO: Soluble; Ethanol: Soluble; Methanol: Soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4091 mL | 7.0455 mL | 14.0911 mL |
| 5 mM | 0.2818 mL | 1.4091 mL | 2.8182 mL |
| 10 mM | 0.1409 mL | 0.7046 mL | 1.4091 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *